RSF1 and Not Cyclin D1 Gene Amplification May Predict Lack of Benefit from Adjuvant Tamoxifen in High-Risk Pre-Menopausal Women in the MA.12 Randomized Clinical Trial

Most women with estrogen receptor expressing breast cancers receiving anti-estrogens such as tamoxifen may not need or benefit from them. Besides the estrogen receptor, there are no predictive biomarkers to help select breast cancer patients for tamoxifen treatment. CCND1 (cyclin D1) gene amplificat...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Keilty, Dana, Buchanan, Marguerite, Ntapolias, Katerina, Aleynikova, Olga, Tu, Dongsheng, Li, Xiao, Shepherd, Lois, Bramwell, Vivien, Basik, Mark
פורמט: Artigo
שפה:Inglês
יצא לאור: Public Library of Science 2013
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3868649/
https://ncbi.nlm.nih.gov/pubmed/24367492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0081740
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים